Lupin to launch additional products to strengthen its branded portfolio

19 Aug 2013 Evaluate

With an aim to strengthen its branded portfolio, Pharma major Lupin, would be launching additional products either from its pipeline or from strategic brand acquisitions that have been developed and filed with the USFDA.

The company's US revenues grew by 54% to Rs 3,683 crore during FY 2013, up from Rs 2,393 crore in FY 2012. Meanwhile, new launches contributed 42% of the US generics revenues.

Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

Lupin Share Price

2094.00 -3.65 (-0.17%)
08-Dec-2025 09:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1796.25
Dr. Reddys Lab 1274.40
Cipla 1512.50
Zydus Lifesciences 934.40
Lupin 2094.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×